Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levocarnitine to Reduce Asparaginase Hepatotoxicity in ALL
NCT05501899Phase 1Recruiting
- Sponsor
- Children's Hospital of Orange County
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of levocarnitine in hepatotoxicity (2 arms), sponsored by Children's Hospital of Orange County. Primary endpoints: Reduction of Hepatotoxicity at 1.5 years and Association between ethnicity and liver function test abnormalities at 1.5 years. Started Mar 2023; status: recruiting.
02
Drugs
levocarnitine
03
Conditions
hepatotoxicity
Beyond the preview
Go deeper on NCT05501899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501899.